Please login to the form below

Not currently logged in

GSK to acquire stake in Aspen

GSK is to take a 16 per cent stake in Aspen Pharmacare Holdings - Africa's biggest generic drug maker

GlaxoSmithKline (GSK) is to take a 16 per cent stake in Aspen Pharmacare Holdings - Africa's biggest generic drug maker. The deal, based on transfer of assets and subject to regulatory approvals, is said to be worth 3.47bn rand ($418m).

Aspen acquires the rights for its subsidiary company, Pharmacare, to distribute GSK products in South Africa and will collaborate with GSK on marketing and selling prescription products in sub-Saharan Africa (except South Africa, Lesotho and Swaziland). A newly formed subsidiary will acquire GSK's manufacturing facility in Bad Oldesloe, Germany. Aspen Global will acquire eight products for worldwide distribution: the chemotherapy drugs Leukeran, Purinethol and Alkeran (excluding US); Kemadrin – for Parkinson's disease; Lanvis and Myleran – for leukaemia; Septrin – a broad-spectrum antimicrobial; and Trandate – for hypertension.

GSK and Aspen have collaborated on a number of projects in recent years. Among other ventures, Aspen distributes some of GSK's prescription products in South Africa, was licensed to manufacture antiretrovirals before patent expiry and distributes GSK's OTC products in Australia.

12th May 2009


Featured jobs

Subscribe to our email news alerts


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...